What You Can Expect from the 6th In-House Impact: Biopharma Summit
In 2025, In-House Impact: Biopharma returns with sharper insights, timely strategies, and a renewed focus on legal’s strategic value. With shifting priorities and rising pressure to cut costs while managing risk, this year’s summit couldn’t be more critical.
Now in its 6th year, the summit continues to be the go-to meeting point for in-house counsel driving innovation and impact in biopharma. You’ll hear how leading legal teams are navigating uncertainty, adopting cutting-edge tech, and strengthening their legal strategy.
Top 5 Unmissable Highlights
Learn how Assertio Therapeutics balances FDA, EMA, and international regulatory expectations for streamlined approvals and adapts to global data privacy requirements
Deep dive into guiding leadership through high-pressure situations with Lexeo Therapeutics, balancing legal risks with business priorities during crises
Discover how Insitro leverages AI to transform drug discovery, development, and regulatory strategies across the drug lifecycle
Gain insights into how Takeda Pharmaceutical, Foundation Medicine, Bristol Myers Squibb, and the Asian American Bar Association of NY are addressing inclusion policies in a politically charged landscape
Explore how Sobi NA, Numab Therapeutics, Olema Oncology, and Kura Oncology are targeting acquisitions to fuel growth, best practices for structuring deals and navigating post-merger integration.
“Dynamic audience interaction was what stood out the most. Also quality of presenters and profile of attendees, as well as very timely topics.”
Arena Therapeutics